Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Oct;40(10):2318–2320. doi: 10.1128/aac.40.10.2318

Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.

K Chin 1, S Merali 1, M Sarić 1, A B Clarkson Jr 1
PMCID: PMC163527  PMID: 8891137

Abstract

The rapid depletion of Pneumocystis carinii polyamines caused by in vitro exposure to DL-alpha-difluoromethylornithine (DFMO; also called eflornithine or Ornidyl) and the rapid repletion following removal of this drug suggested that the in vivo efficacy of DFMO against P. carinii pneumonia (PCP) may be limited by troughs in drug concentration resulting from the schedule of administration. This led to the prediction that, compared with the response to the standard animal protocol of administering DFMO in drinking water, the response of a rat model of PCP to DFMO would be lessened by bolus administration and improved by continuous infusion. These predictions were confirmed. Intraperitoneal bolus administration of up to 3 g of DFMO kg of body weight-1 was completely ineffective, although this dose has been shown to be effective when given in the drinking water. Conversely, continuous infusion improved the response against PCP seven- to ninefold over the response to drinking water administration. These findings suggest that, compared with the standard clinical investigational protocol for treatment of PCP with DFMO given in four divided daily doses, continuous infusion combined with monitoring of drug concentrations in plasma may improve efficacy and/or reduce the already low rate of adverse effects.

Full Text

The Full Text of this article is available as a PDF (169.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abeloff M. D., Slavik M., Luk G. D., Griffin C. A., Hermann J., Blanc O., Sjoerdsma A., Baylin S. B. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis. J Clin Oncol. 1984 Feb;2(2):124–130. doi: 10.1200/JCO.1984.2.2.124. [DOI] [PubMed] [Google Scholar]
  2. Bozzette S. A., Finkelstein D. M., Spector S. A., Frame P., Powderly W. G., He W., Phillips L., Craven D., van der Horst C., Feinberg J. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995 Mar 16;332(11):693–699. doi: 10.1056/NEJM199503163321101. [DOI] [PubMed] [Google Scholar]
  3. Clarkson A. B., Jr, Sarić M., Grady R. W. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Sep;34(9):1833–1835. doi: 10.1128/aac.34.9.1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clarkson A. B., Jr, Williams D. E., Rosenberg C. Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Aug;32(8):1158–1163. doi: 10.1128/aac.32.8.1158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cushion M. T., Stanforth D., Linke M. J., Walzer P. D. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob Agents Chemother. 1985 Dec;28(6):796–801. doi: 10.1128/aac.28.6.796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Golden J. A., Sjoerdsma A., Santi D. V. Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome. West J Med. 1984 Nov;141(5):613–623. [PMC free article] [PubMed] [Google Scholar]
  7. Grove J., Fozard J. R., Mamont P. S. Assay of alpha-difluoromethylornithine in body fluids and tissues by automatic amino-acid analysis. J Chromatogr. 1981 May 8;223(2):409–416. doi: 10.1016/s0378-4347(00)80114-0. [DOI] [PubMed] [Google Scholar]
  8. Haegele K. D., Alken R. G., Grove J., Schechter P. J., Koch-Weser J. Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther. 1981 Aug;30(2):210–217. doi: 10.1038/clpt.1981.150. [DOI] [PubMed] [Google Scholar]
  9. Hughes W. T., Smith B. L. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1984 Oct;26(4):436–440. doi: 10.1128/aac.26.4.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lipschik G. Y., Masur H., Kovacs J. A. Polyamine metabolism in Pneumocystis carinii. J Infect Dis. 1991 May;163(5):1121–1127. doi: 10.1093/infdis/163.5.1121. [DOI] [PubMed] [Google Scholar]
  11. Merali S., Chin K., Grady R. W., Weissberger L., Clarkson A. B., Jr Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. Antimicrob Agents Chemother. 1995 Jul;39(7):1442–1444. doi: 10.1128/aac.39.7.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Merali S., Clarkson A. B., Jr Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine. Antimicrob Agents Chemother. 1996 Apr;40(4):973–978. doi: 10.1128/aac.40.4.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Milord F., Loko L., Ethier L., Mpia B., Pépin J. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):473–477. doi: 10.1016/0035-9203(93)90044-q. [DOI] [PubMed] [Google Scholar]
  14. Paulson Y. J., Gilman T. M., Heseltine P. N., Sharma O. P., Boylen C. T. Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Chest. 1992 Jan;101(1):67–74. doi: 10.1378/chest.101.1.67. [DOI] [PubMed] [Google Scholar]
  15. Pesanti E. L., Bartlett M. S., Smith J. W. Lack of detectable activity of ornithine decarboxylase in Pneumocystis carinii. J Infect Dis. 1988 Nov;158(5):1137–1138. doi: 10.1093/infdis/158.5.1137. [DOI] [PubMed] [Google Scholar]
  16. Sahai J., Berry A. J. Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. Pharmacotherapy. 1989;9(1):29–33. doi: 10.1002/j.1875-9114.1989.tb04100.x. [DOI] [PubMed] [Google Scholar]
  17. Sarić M., Clarkson A. B., Jr Ornithine decarboxylase in Pneumocystis carinii and implications for therapy. Antimicrob Agents Chemother. 1994 Nov;38(11):2545–2552. doi: 10.1128/aac.38.11.2545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sattler F. R., Feinberg J. New developments in the treatment of Pneumocystis carinii pneumonia. Chest. 1992 Feb;101(2):451–457. doi: 10.1378/chest.101.2.451. [DOI] [PubMed] [Google Scholar]
  19. Smith D. E., Davies S., Smithson J., Harding I., Gazzard B. G. Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients. AIDS. 1992 Dec;6(12):1489–1493. doi: 10.1097/00002030-199212000-00011. [DOI] [PubMed] [Google Scholar]
  20. Smith D., Davies S., Nelson M., Youle M., Gleeson J., Gazzard B. Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. AIDS. 1990 Oct;4(10):1019–1021. doi: 10.1097/00002030-199010000-00012. [DOI] [PubMed] [Google Scholar]
  21. Vöhringer H. F., Arastéh K. Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin Pharmacokinet. 1993 May;24(5):388–412. doi: 10.2165/00003088-199324050-00004. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES